To find more information on °×С½ãÂÛ̳H Early Phase Cancer Clinical Trials, including eligibility criteria, click theÌýhyperlinkedÌýLocal Project Reference (LRP)ÌýID, which will take you to the °×С½ãÂÛ̳H Find a Study database.
Additional early phase clinical trials recruiting UrologyÌýcohorts may be found in theÌýAdvanced Solid Tumour Trials Portfolio page.
Ìý
Ìý
DURANCEDURANCE: ÌýA phase Ib/II study to assess the safety and activity of DURvalumab (MEDI4736) in combination with S-488210/S-488211 vAccine in Non-muscle invasive bladder CancEr | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr. Mark Linch |
Drug Class/ Treatment: | Durvalumab (PD-L1 Blocking IgG1 Kappa Monoclonal Antibody)Ìý+ÌýS-488210/S-488211 (Peptide Vaccine) |
Patient Population: | Non-Muscle Invasive Bladder Cancer |
Trial Hosted By - °×С½ãÂÛ̳H Cancer Clinical Trials Unit (CCTU) |
ABACUS-2ABACUS-2: ÌýPhase 2 study of neoadjuvant immune checkpoint inhibitors in urothelial cancer | |
---|---|
Local Project Reference: | |
Principal Investigator: | Dr. Mark Linch |
Drug Class/ Treatment: | AtezolizumabÌý(IgG1 Isotype Monoclonal Antibody against PD-L1) |
Patient Population: | Patient requiring surgery with:
|
Trial Hosted By - °×С½ãÂÛ̳H Cancer Clinical Trials Unit (CCTU) |
Ìý
Ìý
Ìý
Ìý
Ìý